Test Price
2,800 AED✅ Home Collection Available
NPM1 Gene Exon 11 Sequencing (NGS) Test in UAE | AED 2800 | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified NGS Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Daily 8 AM – 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance by a DHA-licensed Consultant Medical Geneticist.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731 (instant confirmation).
Test Overview & Methodology
NPM1 gene exon 11 selective sequencing is a precise molecular diagnostic tool that identifies point mutations and small insertions/deletions in the nucleophosmin gene. These mutations are the most frequent genetic abnormalities in adult acute myeloid leukemia (AML) and serve as essential biomarkers for risk stratification, treatment response prediction, and minimal residual disease (MRD) monitoring. Our NGS‑based assay delivers comprehensive exon 11 coverage with variant allele frequency sensitivity down to 0.1%, ensuring early detection of clonal evolution.
| Feature | Our NGS Test (NPM1 Exon 11) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Analytical Sensitivity | ≥99.9% (detects mutations at ≥1% VAF) | ~95% (misses low‑level clones) |
| Methodology | Next Generation Sequencing (NGS) with bioinformatics validation | Conventional Sanger sequencing |
| Turnaround Time | 3‑4 Weeks (expedited upon request) | 4‑6 Weeks |
| Regulatory Compliance | UAE DHA, MOHAP, ISO 9001:2015, PDPL | Often non‑accredited ISO |
| Clinical Report | Comprehensive, DHA‑endorsed interpretation with ICD‑10 coding | Basic mutation presence/absence |
Physician Insight & Safety Protocols
“As a Consultant Medical Geneticist, I have guided many families through the uncertainty of a myeloid malignancy diagnosis. The NPM1 exon 11 sequencing test is a cornerstone of modern AML management because it directly influences therapeutic intensity and transplant decisions. However, this genetic result must be integrated with complete blood counts, marrow morphology, and clinical presentation. It is never a standalone answer.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
⚠️ Do Not Alter Your Treatment
Do not discontinue or modify any prescribed chemotherapy, targeted therapy, or supportive medication without consulting your treating oncologist. The test result is a decision‑support tool, not a substitute for ongoing clinical supervision.
Exclusion Criteria & Emergency Red Flags
🚨 Emergency Guidance
- Exclusion: This test is indicated only for individuals with a confirmed or suspected diagnosis of AML, myeloid sarcoma, or clonal cytopenia of undetermined significance under the care of a hematologist‑oncologist. It is not intended for general population screening or asymptomatic “biohacking” purposes.
- If you experience any of the following after sample collection, proceed to the nearest emergency department immediately: acute onset of fever ≥38.3°C with neutropenia, uncontrolled bleeding or extensive bruising, sudden severe shortness of breath, new confusion, or chest pain. These symptoms may indicate a life‑threatening complication of underlying leukemia.
- For minors: In accordance with UAE Child Protection Law (Wadeema’s Law) and DHA regulations, genetic testing on individuals under 18 years requires written informed consent from the legal guardian and a pre‑test genetic counselling session documenting the pedigree chart.
Patient FAQ & Clinical Guidance
1. What is the NPM1 exon 11 sequencing test used for?
This NGS test detects mutations in the NPM1 gene to diagnose, prognosticate, and monitor minimal residual disease in acute myeloid leukemia. Mutations in exon 11 are the most common genetic aberration in adult AML and directly influence whether the patient can be treated with standard chemotherapy alone or may require allogeneic stem cell transplantation. The assay measures the exact variant allele frequency, allowing oncologists to track treatment response over time with high precision.
2. How is the sample collected for this genetic test in the UAE?
A simple blood draw or a single drop of blood on a specialized FTA card is collected at your home or office through our VIP mobile phlebotomy service, preserving cold‑chain integrity. Our DHA‑licensed phlebotomists use a rigorous ISO‑certified cold‑chain protocol from collection to lab accession. We come to you across all Emirates between 8 AM and 11 PM, seven days a week.
3. Is this covered by UAE health insurance?
Most UAE medical insurance policies cover NPM1 testing when ordered by a DHA‑licensed hematologist‑oncologist as part of a medically indicated AML workup or follow‑up. Our dedicated insurance verification team will confirm your coverage within minutes via WhatsApp at +971 54 548 8731 before scheduling the home collection. We handle all direct billing and pre‑approval documentation so you can focus on your health.
UAE Regulatory & Data Privacy Adherence
Compliance & Data Protection
All genetic testing services comply with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Genetic data is stored on encrypted, UAE‑based servers and is never shared without explicit consent. Our laboratory holds ISO 9001:2015 certification and is licensed under DHA Facility License No. 1143. For minors, testing adheres to UAE Child Protection Law (Wadeema’s Law). Patient safety and clinical relevance follow Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | NPM1 Gene Exon 11 Sequencing (NGS) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks (expedited available) |
| Sample Type / Matrix | Peripheral Whole Blood or Dried Blood Spot (FTA Card) |
| Methodology Used | Next Generation Sequencing (NGS) with Bioinformatics Analysis |
| ICD-10-CM Code | C92.0 (Acute myeloid leukemia) |
| LOINC Code | 94438-0 |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians